ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pegfilgrastim

Also written as “Pegfilgrastim”, “CHS-1701” and “QL0605(PEG-rhG-CSF)”.

Its studies are mostly in Neutropenia · Breast Neoplasms · Lymphoma, Non-Hodgkin · Lymphoma · Febrile Neutropenia, led by 21 companies.

Drug pagePegfilgrastim: every studyMany companies study it; this page follows only the 47 they lead. All 136 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 21, 200547 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgenits history only150 open or runningphase 4since Jun 21, 2005May 3, 2002none ahead
Dong-A STits history only30 open or runningphase 3since Jan 19, 2012Jan 19, 2012none ahead
Kyowa Kirinits history only30 open or runningphase 2since Aug 14, 2006Aug 14, 2006none ahead
Adello Biologicsits history only20 open or runningphase 1since Apr 12, 2017Apr 12, 2017none ahead
Coherus Biosciencesits history only20 open or runningphase 1since Apr 8, 2015Apr 8, 2015none ahead
Fresenius Kabiits history only20 open or runningphase 1since Aug 14, 2017Aug 14, 2017none ahead
Hangzhou Jiuyuan Gene Engineeringits history only20 open or runningphase 2since Aug 6, 2013Jul 2, 2012none ahead
Intas Pharmaceuticals20 open or runningphase 1since Jul 8, 2019Jul 8, 2019none ahead
Merckleits history only20 open or runningphase 1since Apr 18, 2012Apr 18, 2012none ahead
Mundipharmaits history only20 open or runningphase 1since Dec 10, 2015Dec 10, 2015none ahead

Also a collaborator on its studies: Lambda Therapeutic Research, Celerion and Symyoo.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Intas Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 8, 2019First studies: 2 phase 1 studiesFirst studyNCT04015232, NCT04014062

TargetBeta

CSF3 →CSF3R →read by rule
“A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity”NCIt, by rule
“Granulocyte colony stimulating factor receptor agonist”ChEMBL 37, by rule

Studies

All 2 Intas Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04015232Immunogenicity · India1CompletedJun 5, 2018200
NCT04014062Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers · India1CompletedMay 1, 2018144

How it is read

Names in the registry

  • “Pegfilgrastim”, 13 entries
  • “pegfilgrastim”, 12 entries
  • “CHS-1701”, 3 entries
  • “QL0605(PEG-rhG-CSF)”, 2 entries
  • “lipegfilgrastim”, 2 entries

Codes read as this program: TPI120.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.